arrow
C

Christophe Corpechot

european reference network on hepatological diseases
H指数:58
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Seladelpar improves liver stiffness in PBC: ASSURE interim analysis

Seladelpar改善原发性胆汁性胆管炎患者的肝硬度:ASSURE中期分析

2026-10-060
OA
RIPK1 inhibition reduces biliary injury and fibrosis in primary sclerosing cholangitis

RIPK1抑制可减轻原发性硬化性胆管炎的胆管损伤和纤维化。

2025-12-170
OA
ABCB4 disease-causing variants S242R, S346I, T437I and T1077M significantly impair its function and display differential sensitivity to potentiators

ABCB4疾病致病变体S242R、S346I、T437I和T1077M显著损害其功能,并表现出对增强剂的不同敏感性。

2025-11-220
OAAI
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis

肝硬度测量的预后价值与生化反应在原发性胆汁性胆管炎中的比较

2025-10-030
PRE
Epidemiology, Comorbidity, Treatment and Outcome of Autoimmune Liver Diseases: A French Nationwide Study

自身免疫性肝病:流行病学、合并症、治疗与结局——一项法国全国性研究

2025-08-110
OAAI
Development of a Question Prompt List for People Living With Primary Biliary Cholangitis: A Delphi Study

原发性胆汁性胆管炎患者提问提示清单的开发:一项德尔菲研究

2025-04-150
OAAI
Fibrate-Oca (FI-OCA) Study-a Global snapshot of PBC practice around the Globe
2025-03-010
PRE
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis

肝脏硬度测量的动力学和原发性胆汁性胆管炎的临床过程

2024-12-011
OAAI
Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Interim Results for 2 Years From the ASSURE Study

开放标签下塞拉德帕治疗原发性胆汁性胆管炎的长期有效性与安全性:ASSURE研究2年期的中期结果

2024-10-010
PRE
Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with primary biliary cholangitis - an ELTR study
2024-08-010
OAAI
The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial
2024-04-0111
PRE
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis

Seladelpar在原发性胆汁性胆管炎中的3期试验

2024-02-2932
PRE